Back to Journals » Vascular Health and Risk Management » Volume 8

Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities

Authors Fuchs F, Fuchs, Moreira L, Gus

Received 3 April 2012

Accepted for publication 9 May 2012

Published 12 July 2012 Volume 2012:8 Pages 437—442

DOI https://doi.org/10.2147/VHRM.S32585

Review by Single-blind

Peer reviewer comments 4

Flavio Danni Fuchs, Sandra Costa Fuchs, Leila Beltrami Moreira, Miguel Gus

Division of Cardiology and Postgraduate Studies Program in Cardiology, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

Abstract: High blood pressure and lipoprotein abnormalities were identified by many cohort studies as the major risk factors for cardiovascular disease. Laboratory experiments apparently confirmed their role in the causation of atherosclerosis, but a proof of concept requires the corroboration by clinical trials in human beings. The size of benefit in clinical trials regarding the control of high blood pressure was within the estimations of risk provided by cohort studies. For a reduction of 10 mmHg in systolic blood pressure or 5 mmHg in diastolic blood pressure, the relative risk reduction of coronary heart disease was 22% (95% confidence interval 27%–17%) in a meta-analysis of clinical trials, close to the estimation of reduction of 25% (95% confidence interval 23%–27%) provided by a meta-analysis of cohort studies. The corresponding values for stroke were 41% (95% confidence interval 33%–48%) in clinical trials compared to a cohort risk prediction of 36% (95% confidence interval 34%–38%). This efficacy was shared by all blood pressure-lowering drugs. The same figure has not paradoxically happened with drugs that act over abnormalities of cholesterol and lipoproteins. Only statins, which have other beneficial actions as well, have consistently lowered the incidence of cardiovascular diseases, an efficacy that was not reproduced by older and newer quite potent lipid drugs. The adverse effects of these drugs may nullify their beneficial effects over lipoproteins and abnormalities of lipoproteins may only be surrogate markers of the underlying real risks.

Keywords: proof of concept, hypertension, lipoproteins, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]